Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma

Abstract

Among patients with persistent asthma that remains suboptimally controlled with the use of inhaled corticosteroids, US guidelines suggest a stepwise approach to modifying therapy that includes increasing the dose of inhaled corticosteroids or adding adjunctive therapies.¹ Inhaled long-acting β-agonists (LABAs) are the preferred adjunctive therapy for patients aged 12 years or older and are considered 1 of several potential adjunctive therapies for patients aged 5 to 11 years.